These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 26284152)
21. Unmet medical needs for chronic spontaneous urticaria patients: highlighting the real-life clinical practice in Taiwan. Cho YT; Pao YC; Chu CY J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):41-9. PubMed ID: 26428436 [TBL] [Abstract][Full Text] [Related]
22. The Impact of Chronic Urticaria from the Patient's Perspective: A Survey in Five European Countries. Balp MM; Vietri J; Tian H; Isherwood G Patient; 2015 Dec; 8(6):551-8. PubMed ID: 26476961 [TBL] [Abstract][Full Text] [Related]
23. State of the art of chronic spontaneous urticaria in Italy: a multicentre survey to evaluate physicians' and patients' perspectives. Rimoldi M; Rossi O; Rota N BMJ Open; 2016 Oct; 6(10):e012378. PubMed ID: 27742625 [TBL] [Abstract][Full Text] [Related]
24. Effects of Vaccination against COVID-19 in Chronic Spontaneous and Inducible Urticaria (CSU/CIU) Patients: A Monocentric Study. Grieco T; Ambrosio L; Trovato F; Vitiello M; Demofonte I; Fanto M; Paolino G; Pellacani G J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407429 [TBL] [Abstract][Full Text] [Related]
25. A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria. Friedman A; Kwatra SG; Yosipovitch G Dermatol Ther (Heidelb); 2024 Jun; 14(6):1371-1387. PubMed ID: 38758422 [TBL] [Abstract][Full Text] [Related]
26. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128 [TBL] [Abstract][Full Text] [Related]
27. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097 [TBL] [Abstract][Full Text] [Related]
28. Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study. Danilycheva I; Emelyanov A; Meshkova R; Ukhanova O; Abdrakhmanov A; Litvin L Postepy Dermatol Alergol; 2022 Jun; 39(3):509-516. PubMed ID: 35950113 [TBL] [Abstract][Full Text] [Related]
29. Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. Lima H; Gooderham M; Dutz J; Lynde C; Chapdelaine H; Ellis A; Gilbert M; Ho V; Papp K; Poulin Y; Sussman G Allergy Asthma Clin Immunol; 2017; 13():38. PubMed ID: 28852410 [TBL] [Abstract][Full Text] [Related]
31. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Kolkhir P; Altrichter S; Hawro T; Maurer M Allergy; 2018 Apr; 73(4):940-948. PubMed ID: 29130488 [TBL] [Abstract][Full Text] [Related]
33. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. Thomsen SF; Pritzier EC; Anderson CD; Vaugelade-Baust N; Dodge R; Dahlborn AK; Vestergaard C J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1048-1055. PubMed ID: 28294420 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. Kanters TA; Thio HB; Hakkaart L Br J Dermatol; 2018 Sep; 179(3):702-708. PubMed ID: 29476533 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. Hide M; Park HS; Igarashi A; Ye YM; Kim TB; Yagami A; Roh J; Lee JH; Chinuki Y; Youn SW; Lee SK; Inomata N; Choi JH; Fukunaga A; Wang J; Matsushima S; Greenberg S; Khalil S J Dermatol Sci; 2017 Jul; 87(1):70-78. PubMed ID: 28366435 [TBL] [Abstract][Full Text] [Related]
36. Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria. Liang SE; Hoffmann R; Peterson E; Soter NA JAMA Dermatol; 2019 Jan; 155(1):90-95. PubMed ID: 30476976 [TBL] [Abstract][Full Text] [Related]
37. Dupilumab as Add-on Therapy for Management of Chronic Spontaneous Urticaria. Kudlaty E; Newell P; Chovatiya R J Clin Aesthet Dermatol; 2024 Jan; 17(1):10-12. PubMed ID: 38298750 [TBL] [Abstract][Full Text] [Related]
38. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. Casale TB; Bernstein JA; Maurer M; Saini SS; Trzaskoma B; Chen H; Grattan CE; Gimenéz-Arnau A; Kaplan AP; Rosén K J Allergy Clin Immunol Pract; 2015; 3(5):743-50.e1. PubMed ID: 26054553 [TBL] [Abstract][Full Text] [Related]
39. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study. Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658 [TBL] [Abstract][Full Text] [Related]
40. Comparative Study of Positive Versus Negative Autologous Serum Skin Test in Chronic Spontaneous Urticaria and its Treatment Outcome. Kumar YH; Bhaskar S; Shankar K N Am J Med Sci; 2016 Jan; 8(1):25-30. PubMed ID: 27011944 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]